Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aida Pharmaceuticals, Inc.
Aida Pharmaceuticals reports 11% increase in revenue
June 23rd, 2006
Aida Pharmaceuticals, Inc., (AIDA) a pharmaceutical firm in China, announced its financial results for the first quarter ended March 31, 2006. Revenues in the first quarter of 2006 increased by $531,214, or 11.1%, to $5,331,827, versus revenues of $4,800,613 in the first quarter of 2005. Reflecting the company's current strategic focus on intense promotion of new Etimicin transfusion and injection products, Etimicin transfusion revenues increased 72.66% quarter-over-quarter and Etimicin injection revenues increased 85.55% quarter-over-quarter. Gross profit in the first quarter of 2006 declined 30%, to $2,348,713, versus $3,364,753 in the first...
Source: Biotech Law Weekly (2006-06-23)
|
